More results are out from a trial of Roche’s Tecentriq in lung cancer, but industry watchers still don’t have many of the answers they’re looking for.
On Thursday, Roche unveiled positive results from its first-line lung-cancer combo trial—but those results raised more questions than they provided answers.
There’s no stopping time…but these Patient Recruitment & Retention tactics can help overcome trial delays. Our global late-stage study expert discusses…
All these years after its initial approval, Pfizer's little blue pill Viagra is coming to the end of its patent life.
Philippines' health secretary plans to ask Sanofi for a Dengvaxia refund and to sue the drugmaker amid worries about the dengue shot's safety.
A new report found that spending on pharmaceuticals grew at a much slower rate last year than in recent history.
Merck's appeal to the Supreme Court has drawn in the U.S. Solicitor General, and the outcome could reverberate across the pharmaceutical industry.
Two Swiss pharma giants got some news out of England Tuesday that they weren’t too excited about.
Dark social media may sound sinister, but it's actually just a growing way that people share content on social media, and pharma companies should be…
It’s an A-plus for J&J and Sanofi. The second annual Good Pharma Scorecard assigned both drugmakers perfect scores of 100% for trial transparency.
Clovis is one step away from a new use for its ovarian cancer drug Rubraca—and with FDA priority review, it could take that step early next year.